Checkpoint kinase 2 (Chek2) mediates therapeutic resistance to CD8+ T cell recognition, and both genetic depletion or pharmacologic inhibition of Chek2 increase survival in combination with immune checkpoint blockade through STING activation in preclinical glioma models (21). The gene discussed is STING1; the disease is central nervous system cancer.